Advances in Genetic Engineering & BiotechnologyISSN: 2324-9021

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Editorial, Adv Genet Eng Biotechnol Vol: 1 Issue: 1

Omics-Based CHO Cell Engineering Entrance into Post-Genomic Era

Yeon-Gu Kim*
1Biotechnology Process Engineering Center, KRIBB, Daejon 305-806, Korea
Corresponding author : Dr. Yeon-Gu Kim
Biotechnology Process Engineering Center, KRIBB, Daejon 305-806, Korea
Tel: 82-42-860-4512; Fax: 82-42-860-4529
E-mail: [email protected]
Received: July 20, 2012 Accepted: July 23, 2012 Published: July 27, 2012  doi:10.4172/2324-9021.1000e103
Citation: Kim YG (2012) Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era. Adv Genet Eng Biotechnol 1:1. doi:10.4172/2324-9021.1000e103

Abstract

Omics-Based CHO Cell Engineering – Entrance into Post-Genomic Era

Chinese hamster ovary cells (CHO) cells have been the most commonly used mammalian host for the production of therapeutic proteins since the first therapeutic protein from recombinant mammalian cells, tissue plasminogen activator (tPA, Genentech, USA) synthesized in CHO cells, was approved for clinical use in 1987. Despite the availability of various mammalian cell lines (such as BHK, HEK-293, HeLa, NS0, and PerC6), nearly 70% of all recombinant protein therapeutics produced today are made in CHO cells.

Keywords:

Track Your Manuscript

Share This Page